MBX Biosciences (MBX) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
6 Aug, 2026Strategic focus and mission
Focused on developing precision peptide therapies for endocrine and metabolic diseases, aiming to transform patient lives through innovative drug design.
Proprietary PEP platform enables multi-mechanism peptides, programmable prodrugs, and fatty acylation for optimized dosing and efficacy.
Financial position and milestones
Holds $418.6 million in cash, projected to fund operations into 2029.
Key 2026 milestones include Phase 3 initiation for canvuparatide, Phase 1 MAD results for MBX 4291 and MBX 5765, and development candidate nomination for MBX 6180.
Endocrine pipeline: Canvuparatide for hypoparathyroidism
Canvuparatide is a once-weekly PTH replacement therapy in pivotal Phase 3 for chronic hypoparathyroidism.
Phase 2 data show competitive responder rates versus daily injectable therapies, with potential to become new standard of care.
Phase 3 trial includes a 26-week double-blind period and 78-week open-label extension, focusing on normalization of serum calcium and independence from supplements.
Latest events from MBX Biosciences
- Q4 MBX 4291 data will shape phase IIb plans as canvuparatide phase III advances.MBX
Jefferies Global Healthcare Conference - Canvuparatide advances in phase III as monthly obesity assets progress toward key data.MBX
3rd Annual Guggenheim Healthcare Innovation Conference - Canvuparatide Phase 3 began; $481.6M in liquidity supported runway into 2029.MBX
Q3 2026 - Advancing once-weekly and once-monthly peptide therapies with strong clinical and market momentum.MBX
Stifel 2026 Virtual Cardiometabolic Forum - Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027.MBX
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 net loss rose to $37.1M as R&D spending increased; cash reserves support operations into 2029.MBX
Q2 2026 - Phase III for once-weekly canvuparatide starts Q3 2024, with major 2026 data and strong financials.MBX
Piper Sandler 37th Annual Healthcare Conference - Once-weekly canvuparatide showed durable efficacy and safety at one year, supporting Phase III advancement.MBX
Study result - All director and auditor proposals were approved by stockholders at the annual meeting.MBX
AGM 2026